BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

613 related articles for article (PubMed ID: 28931688)

  • 1. A Selective Bottleneck Shapes the Evolutionary Mutant Spectra of Enterovirus A71 during Viral Dissemination in Humans.
    Huang SW; Huang YH; Tsai HP; Kuo PH; Wang SM; Liu CC; Wang JR
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28931688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enterovirus A71 Induces Neurological Diseases and Dynamic Variants in Oral Infection of Human SCARB2-Transgenic Weaned Mice.
    Lin JY; Weng KF; Chang CK; Gong YN; Huang GJ; Lee HL; Chen YC; Huang CC; Lu JY; Huang PN; Chiang HJ; Chen CM; Shih SR
    J Virol; 2021 Oct; 95(21):e0089721. PubMed ID: 34379497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enterovirus A71 Containing Codon-Deoptimized VP1 and High-Fidelity Polymerase as Next-Generation Vaccine Candidate.
    Tsai YH; Huang SW; Hsieh WS; Cheng CK; Chang CF; Wang YF; Wang JR
    J Virol; 2019 Jul; 93(13):. PubMed ID: 30996087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Electrostatic interactions at the five-fold axis alter heparin-binding phenotype and drive enterovirus A71 virulence in mice.
    Tee HK; Tan CW; Yogarajah T; Lee MHP; Chai HJ; Hanapi NA; Yusof SR; Ong KC; Lee VS; Sam IC; Chan YF
    PLoS Pathog; 2019 Nov; 15(11):e1007863. PubMed ID: 31730673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enterovirus A71 VP1 Variation A289T Decreases the Central Nervous System Infectivity via Attenuation of Interactions between VP1 and Vimentin In Vitro and In Vivo.
    Zhu H; Cao Y; Su W; Huang S; Lu W; Zhou Y; Gao J; Zhao W; Zhang B; Wu X
    Viruses; 2019 May; 11(5):. PubMed ID: 31121933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic evolution of Human Enterovirus A71 subgenotype C4 in Shenzhen, China, 1998-2013.
    He Y; Zou L; Chong MKC; Men R; Xu W; Yang H; Yao X; Chen L; Xian H; Zhang H; Luo M; Cheng J; Ma H; Feng Q; Huang Y; Wang Y; Yeoh EK; Zee BC; Zhou Y; He ML; Wang MH
    J Infect; 2016 Jun; 72(6):731-737. PubMed ID: 27038503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A severe pediatric infection with a novel enterovirus A71 strain, Thuringia, Germany.
    Karrasch M; Fischer E; Scholten M; Sauerbrei A; Henke A; Renz DM; Mentzel HJ; Böer K; Böttcher S; Diedrich S; Krumbholz A; Zell R
    J Clin Virol; 2016 Nov; 84():90-95. PubMed ID: 27771495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rosmarinic acid exhibits broad anti-enterovirus A71 activity by inhibiting the interaction between the five-fold axis of capsid VP1 and cognate sulfated receptors.
    Hsieh CF; Jheng JR; Lin GH; Chen YL; Ho JY; Liu CJ; Hsu KY; Chen YS; Chan YF; Yu HM; Hsieh PW; Chern JH; Horng JT
    Emerg Microbes Infect; 2020 Dec; 9(1):1194-1205. PubMed ID: 32397909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mapping Enterovirus A71 Antigenic Determinants from Viral Evolution.
    Huang SW; Tai CH; Fonville JM; Lin CH; Wang SM; Liu CC; Su IJ; Smith DJ; Wang JR
    J Virol; 2015 Nov; 89(22):11500-6. PubMed ID: 26339057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a full-length cDNA-derived enterovirus A71 vaccine candidate using reverse genetics technology.
    Yang YT; Chow YH; Hsiao KN; Hu KC; Chiang JR; Wu SC; Chong P; Liu CC
    Antiviral Res; 2016 Aug; 132():225-32. PubMed ID: 27387826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intra-host emergence of an enterovirus A71 variant with enhanced PSGL1 usage and neurovirulence.
    Sun L; Tijsma A; Mirabelli C; Baggen J; Wahedi M; Franco D; De Palma A; Leyssen P; Verbeken E; van Kuppeveld FJM; Neyts J; Thibaut HJ
    Emerg Microbes Infect; 2019; 8(1):1076-1085. PubMed ID: 31339457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of three small molecule inhibitors of enterovirus 71 identified from screening of a library of natural products.
    Li G; Gao Q; Yuan S; Wang L; Altmeyer R; Lan K; Yin F; Zou G
    Antiviral Res; 2017 Jul; 143():85-96. PubMed ID: 28412182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amino Acid Variation at VP1-145 of Enterovirus 71 Determines Attachment Receptor Usage and Neurovirulence in Human Scavenger Receptor B2 Transgenic Mice.
    Kobayashi K; Sudaka Y; Takashino A; Imura A; Fujii K; Koike S
    J Virol; 2018 Aug; 92(15):. PubMed ID: 29848584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction between PHB2 and Enterovirus A71 VP1 Induces Autophagy and Affects EV-A71 Infection.
    Su W; Huang S; Zhu H; Zhang B; Wu X
    Viruses; 2020 Apr; 12(4):. PubMed ID: 32276428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human Enterovirus 71 Protein Displayed on the Surface of Saccharomyces cerevisiae as an Oral Vaccine.
    Zhang C; Wang Y; Ma S; Li L; Chen L; Yan H; Peng T
    Viral Immunol; 2016 Jun; 29(5):288-95. PubMed ID: 27259043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VP1 residues around the five-fold axis of enterovirus A71 mediate heparan sulfate interaction.
    Tan CW; Sam IC; Lee VS; Wong HV; Chan YF
    Virology; 2017 Jan; 501():79-87. PubMed ID: 27875780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular characterization of enterovirus-A71 in children with acute flaccid paralysis in the Philippines.
    Apostol LN; Shimizu H; Suzuki A; Umami RN; Jiao MMA; Tandoc A; Saito M; Lupisan S; Oshitani H
    BMC Infect Dis; 2019 May; 19(1):370. PubMed ID: 31046684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viral determinants that drive Enterovirus-A71 fitness and virulence.
    Ang PY; Chong CWH; Alonso S
    Emerg Microbes Infect; 2021 Dec; 10(1):713-724. PubMed ID: 33745413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel Attenuated Enterovirus A71 Mutant with VP1-V238A,K244R Exhibits Reduced Efficiency of Cell Entry/Exit and Augmented Binding Affinity to Sulfated Glycans.
    Meng T; Wong SM; Chua KB
    J Virol; 2021 Oct; 95(22):e0105521. PubMed ID: 34468173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VP1 Amino Acid Residue 145 of Enterovirus 71 Is a Key Residue for Its Receptor Attachment and Resistance to Neutralizing Antibody during Cynomolgus Monkey Infection.
    Fujii K; Sudaka Y; Takashino A; Kobayashi K; Kataoka C; Suzuki T; Iwata-Yoshikawa N; Kotani O; Ami Y; Shimizu H; Nagata N; Mizuta K; Matsuzaki Y; Koike S
    J Virol; 2018 Aug; 92(15):. PubMed ID: 29848582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.